Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Other Working Capital Changes (2019 - 2025)

Historic Other Working Capital Changes for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $122000.0.

  • Eton Pharmaceuticals' Other Working Capital Changes fell 2327.04% to $122000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 51363.64%. This contributed to the annual value of $3.3 million for FY2024, which is 366276.6% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Other Working Capital Changes stood at $122000.0 for Q3 2025, which was down 2327.04% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Other Working Capital Changes ranged from a high of $3.5 million in Q4 2024 and a low of -$3.0 million during Q1 2025
  • For the 5-year period, Eton Pharmaceuticals' Other Working Capital Changes averaged around $99526.3, with its median value being -$79000.0 (2024).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first skyrocketed by 140000.0% in 2021, then tumbled by 366329.11% in 2025.
  • Eton Pharmaceuticals' Other Working Capital Changes (Quarter) stood at $743000.0 in 2021, then crashed by 61.1% to $289000.0 in 2022, then surged by 126.64% to $655000.0 in 2023, then surged by 437.4% to $3.5 million in 2024, then crashed by 96.53% to $122000.0 in 2025.
  • Its last three reported values are $122000.0 in Q3 2025, $2.3 million for Q2 2025, and -$3.0 million during Q1 2025.